Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AN2 Therapeutics, Inc. (Nasdaq: ANTX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AN2 describes itself as a clinical-stage biopharmaceutical company developing novel small molecule therapeutics from its boron chemistry platform, with programs in Chagas disease, melioidosis, NTM lung disease caused by Mycobacterium abscessus, and oncology targets.
Periodic and current reports such as Forms 10-K, 10-Q, and 8-K provide detail on AN2’s research and development expenses, cash position, and progress across its pipeline. For example, recent Form 8-K filings reference press releases reporting quarterly financial results, including operating expenses and net loss, and describe how the company is advancing clinical trials and collaborations. These documents help investors understand how AN2 funds and prioritizes its infectious disease and oncology programs.
Regulatory filings can also disclose capital structure changes. A Form 8-K describes AN2’s issuance of pre-funded warrants in exchange for common stock to an institutional investor, including key terms such as exercise price and beneficial ownership limitations. Such filings give insight into how the company structures financing while managing ownership thresholds.
On this page, users can access AN2’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) once filed, along with current reports (Form 8-K) that cover material events, collaborations, and financial updates. AI-powered summaries on Stock Titan are designed to highlight the main points in lengthy filings, helping readers quickly identify items related to clinical development, cash runway, or capital transactions without reading every line.
Investors interested in AN2’s ongoing work in Chagas disease, melioidosis, NTM lung disease, tuberculosis collaborations, and oncology targets can use the filings page to review the company’s official disclosures and track how its boron chemistry platform is reflected in its regulatory reporting.
AN2 Therapeutics, Inc. reported that officer Joshua M. Eizen had certain stock options repriced on March 19, 2026. He received new options to purchase 92,000 and 50,150 shares of common stock at an exercise price of $3.91 per share, replacing prior options for the same share amounts with higher exercise prices of $17.88 and $14.29.
The footnotes explain that the new exercise price equals the closing market price on the repricing date and that vesting schedules remain as previously set. The filing shows no open-market purchases or sales of common stock, only compensation-related option grants and corresponding cancellations back to the issuer.
AN2 Therapeutics director Melvin K. Spigelman reported a board-approved repricing of his stock options on March 19, 2026. He received three fully vested stock option awards for 16,941, 10,362 and 23,742 underlying common shares at a new exercise price of $3.91 per share, while surrendering an equal number of existing options with higher exercise prices of $9.308, $17.28 and $5.91.
The repriced options keep their original terms except for the exercise price. If any repriced option is exercised, or his service ends, before the “Premium End Date” (the earliest of September 19, 2027, a change in control, or his death or disability), the exercise price reverts to the original higher level. These are compensation-related derivative adjustments, not open-market stock purchases or sales.
AN2 Therapeutics director Robin Shane Readnour reported a repricing of stock options covering 20,724 and 23,742 shares of common stock on March 19, 2026. Existing options with exercise prices of $17.28 and $5.91 per share were returned to the company, and fully vested replacement options were granted at an exercise price of $3.91 per share, equal to the closing stock price on the repricing date.
The footnotes state this new exercise price will revert to the original higher price if the repriced options are exercised, or if Readnour’s service with the company ends, before the defined “Premium End Date,” which is the earliest of September 19, 2027, a change in control, or Readnour’s death or disability.
AN2 Therapeutics Chief Executive Officer Eric Easom reported a repricing of his stock options, with no open-market purchases or sales of common stock. On March 19, 2026, the board approved cancelling existing options with exercise prices of $6.596, $17.28 and $11.99 per share and granting replacement options over the same share amounts at an exercise price of $3.91 per share, matching the closing stock price that day.
The replacement options remain subject to their original expiration dates and vesting schedules, including monthly vesting measured from March 25, 2022 and January 1, 2023, as applicable. The footnotes state that if the repriced options are exercised, or Easom’s service ends, before a defined “Premium End Date,” the exercise price will revert to the original higher levels.
AN2 Therapeutics, Inc. approved a broad stock option repricing on March 19, 2026. All outstanding options granted under its 2017 and 2022 equity incentive plans before that date now have an exercise price of $3.91 per share, matching the common stock closing price on the repricing date.
Holders must still pay the original exercise price if they exercise before the “Premium End Date,” defined as the earliest of September 19, 2027, a change in control, or the holder’s death or disability. All other terms of the options remain unchanged. Named executive officers affected include CEO Eric Easom with 742,649 repriced options, CLO/COO Joshua Eizen with 142,150 options, and CFO Lucy Day with 221,965 options, originally priced between $6.60 and $17.88 per share.
AN2 Therapeutics, Inc. provides an annual overview as a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform. Its lead candidate, oral epetraborole, is being advanced toward Phase 2 studies in phlebotomy-dependent polycythemia vera and Mycobacterium abscessus complex lung disease.
The company is also developing oral AN2-502998 for Chagas disease, with a Phase 1 trial in healthy volunteers nearing completion and a proof-of-concept Phase 2 planned in 2026. Preclinical oncology programs target PI3Kα and ENPP1, with two oncology candidates expected to enter development in 2026, alongside global health programs in melioidosis and tuberculosis funded largely by non-dilutive sources.
AN2 operates via an asset-light model, outsourcing manufacturing and relying on key license agreements with Anacor, Brii Biosciences, Adjuvant Global Health Technology Fund and the University of Georgia Research Foundation. As of June 30, 2025, non-affiliate equity had an aggregate market value of $23,078,812, and 35,941,195 common shares were outstanding as of March 10, 2026.
AN2 Therapeutics reported a 2025 net loss of $35.2M, improved from $51.3M in 2024, as it narrowed research and administrative spending. Fourth-quarter net loss was $8.7M, or $0.29 per share.
Full-year R&D expenses fell to $24.8M from $40.5M, while G&A declined to $13.3M from $14.1M. There were no restructuring charges in 2025, compared with $2.2M a year earlier.
The company ended 2025 with $60.0M in cash, cash equivalents and investments and entered a March 2026 private placement for roughly $40M in gross proceeds. Management projects this funding will support operations into 2029 while advancing Phase 2 programs in polycythemia vera, M. abscessus lung disease and Chagas disease, plus two oncology candidates.
AN2 Therapeutics, Inc. disclosure: Commodore Capital LP, Commodore Capital Master LP and related parties report beneficial ownership of 3,697,435 shares of Common Stock as of March 9, 2026. The total comprises 2,333,713 shares held and 1,363,722 shares issuable upon exercise of a Pre-Funded Warrant. The Pre-Funded Warrant is subject to a 9.99% Beneficial Ownership Limitation. Ownership percentages are calculated using 37,011,357 shares outstanding, derived from the issuer's reported counts as of November 3, 2025 and a private placement closed on or about March 10, 2026.
AN2 Therapeutics, Inc. (ANTX) owners filed a Schedule 13G reporting shared beneficial ownership stakes in Common Stock by a group led by Millennium affiliates and Integrated Core Strategies. The filing lists holdings of 2,237,102 shares (6.3%) for Millennium Management LLC and affiliates and 2,135,044 shares (6.0%) for Integrated Core Strategies (US) LLC.
The percent figures are calculated using 35,647,635 shares outstanding, which the filing ties to the issuer's reported 27,402,024 shares outstanding as of November 3, 2025 plus 8,245,611 shares issued in a private placement closed on or about March 10, 2026. The filing is a joint Schedule 13G with a Joint Filing Agreement dated March 12, 2026.
AN2 Therapeutics reports beneficial ownership by Vivo Opportunity entities. Vivo Opportunity Fund Holdings, L.P. holds 2,864,346 shares of Common Stock (representing 8.0%) and Vivo Opportunity Cayman Fund, L.P. holds 289,294 shares (0.8%), as disclosed in a joint Schedule 13G filing.
The percent calculations are based on 35,647,635 shares outstanding, comprising 27,402,024 shares outstanding as of November 3, 2025 and 8,245,611 shares issued at the closing of a private placement on March 10, 2026.